CRDF — Cardiff Oncology Share Price
0.000.00%
Last trade - 00:00- $194.35m
- $118.45m
- $0.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.74 | ||
| Price to Tang. Book | 2.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 398.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.78% | ||
| Return on Equity | -46.54% | ||
| Operating Margin | -9305.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.24 | 0.37 | 0.36 | 0.39 | 0.49 | 0.24 | 0.07 | 5.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Directors
- Rodney Markin NEC
- Mark Erlander CEO (61)
- James Levine CFO (50)
- Vicki Kelemen COO
- Katherine Ruffner OTH
- James Armitage IND (74)
- John Brancaccio IND (73)
- Mani Mohindru IND (49)
- Gary Pace IND (73)
- Renee Tannenbaum IND (69)
- Lale White IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 21st, 2009
- Public Since
- July 27th, 2004
- No. of Shareholders
- 58
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 44,677,169
- Address
- 11055 Flintkote Ave, SAN DIEGO, 92121-1220
- Web
- https://cardiffoncology.com/
- Phone
- +1 8589527570
- Auditors
- BDO USA, P.C.
Upcoming Events for CRDF
Q2 2024 Cardiff Oncology Inc Earnings Release
Similar to CRDF
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Cardiff Oncology share price?
As of Today at 19:04 UTC, shares in Cardiff Oncology are trading at $4.35. This share price information is delayed by 15 minutes.
How has the Cardiff Oncology share price performed this year?
Shares in Cardiff Oncology last closed at $4.35 and the price had moved by +217.52% over the past 365 days. In terms of relative price strength the Cardiff Oncology share price has outperformed the S&P500 Index by +164.23% over the past year.
What are the analyst and broker recommendations for Cardiff Oncology?
The overall consensus recommendation for Cardiff Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cardiff Oncology dividend yield?
Cardiff Oncology does not currently pay a dividend.
Does Cardiff Oncology pay a dividend?
Cardiff Oncology does not currently pay a dividend.
When does Cardiff Oncology next pay dividends?
Cardiff Oncology does not currently pay a dividend.
How do I buy Cardiff Oncology shares?
To buy shares in Cardiff Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cardiff Oncology?
As of the previous close price of $4.35, shares in Cardiff Oncology had a market capitalisation of $194.35m.
Where are Cardiff Oncology shares listed?
Here are the trading details for Cardiff Oncology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CRDF
What kind of share is Cardiff Oncology?
Based on an overall assessment of its quality, value and momentum Cardiff Oncology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cardiff Oncology share price forecast for 2024?
The analyst consensus target price for shares in Cardiff Oncology is $10.50. That is 141.38% above the last closing price of $4.35.
Analysts covering Cardiff Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
What is the trend in the Cardiff Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cardiff Oncology. Over the past six months, its share price has outperformed the S&P500 Index by +238.81%.
As of the last closing price of $4.35, shares in Cardiff Oncology were trading +106.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cardiff Oncology PE Ratio?
The Cardiff Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cardiff Oncology?
Cardiff Oncology's management team is headed by:
- Rodney Markin - NEC
- Mark Erlander - CEO
- James Levine - CFO
- Vicki Kelemen - COO
- Katherine Ruffner - OTH
- James Armitage - IND
- John Brancaccio - IND
- Mani Mohindru - IND
- Gary Pace - IND
- Renee Tannenbaum - IND
- Lale White - IND